Affimed N.V.

Affimed N.V. is a clinical-stage biopharmaceutical company that focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate, AFM13, has completed Phase II clinical study for peripheral T-cell lymphoma, Phase IIa clinical trial for CD30-positive lymphoma, and Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.

Affimed N.V. has established several strategic collaborations with renowned industry partners such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. The company also has a research funding agreement with The Leukemia & Lymphoma Society. Affimed N.V. was established in 2000 and is headquartered in Heidelberg, Germany. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.

Affimed N.V. is dedicated to developing novel cancer immunotherapies that target natural killer cells and T cells. The company’s lead product candidate, AFM13, is a first-in-class innate cell engager (ICE) that targets CD30-positive lymphomas and is currently in Phase II clinical trials. In addition, Affimed is developing other ICE candidates such as AFM24, AFM28, and AFM32 for the treatment of advanced cancers, acute myeloid leukemia, and solid tumors, respectively.

Affimed N.V. is currently advancing its clinical development programs and continues to expand its collaboration agreements with leading industry partners. Its research funding agreement with The Leukemia & Lymphoma Society has enabled the company to further its mission of developing innovative cancer immunotherapies. As of 2021, Affimed N.V. had a total of approximately 70 employees, including scientists, clinical development professionals, and business development experts.